Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Trial Profile

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms B-FAST
  • Sponsors Roche
  • Most Recent Events

    • 06 Nov 2018 Planned primary completion date changed from 5 Mar 2020 to 13 Feb 2020.
    • 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
    • 10 Oct 2017 Planned End Date changed from 31 Dec 2021 to 2 Jan 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top